UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An oxygen-regulated switch in the protein synthesis machinery

Nature (London), 2012-05, Vol.486 (7401), p.126-129

2012

Volltextzugriff (PDF)

Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer

Proceedings of the National Academy of Sciences - PNAS, 2007-08, Vol.104 (32), p.13092-13097

2007

Volltextzugriff (PDF)

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations

Clinical cancer research, 2017-06, Vol.23 (12), p.2981-2990

2017

Volltextzugriff (PDF)

Human cancers converge at the HIF-2α oncogenic axis

Proceedings of the National Academy of Sciences - PNAS, 2009-12, Vol.106 (50), p.21306-21311

2009

Volltextzugriff (PDF)

MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment

Nature communications, 2016-11, Vol.7 (1), p.13597-13597, Article 13597

2016

Volltextzugriff (PDF)

DNMT3a epigenetic program regulates the HIF-2α oxygen-sensing pathway and the cellular response to hypoxia

Proceedings of the National Academy of Sciences - PNAS, 2014-05, Vol.111 (21), p.7783-7788

2014

Volltextzugriff (PDF)

Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer

Cancer research (Chicago, Ill.), 2005-06, Vol.65 (12), p.5221-5230

2005

Volltextzugriff (PDF)

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort

Frontiers in oncology, 2019-04, Vol.9, p.212-212

2019

Volltextzugriff (PDF)

HIF-2α: Many cancers, one engine?

Cell cycle (Georgetown, Tex.), 2010-03, Vol.9 (5), p.859-860

2010

Volltextzugriff (PDF)

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Journal of clinical oncology, 2021-01, Vol.39 (1), p.57-65

2021

Volltextzugriff (PDF)

An oxygen-regulated switch in the protein synthesis machinery

Nature (London), 2012-06, Vol.486 (7401), p.126-129

2012

Volltextzugriff (PDF)

The next-generation pan-RAF inhibitor, KIN-2787, is active in class II and class III BRAF mutant models

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3116-3116

2021

Volltextzugriff (PDF)

Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9601-TPS9601

2022

Volltextzugriff (PDF)

Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.461-461

2022

Volltextzugriff (PDF)

Integrin αvβ3 Drives Slug Activation and Stemness in the Pregnant and Neoplastic Mammary Gland

Developmental cell, 2014-08, Vol.30 (3), p.295-308

2014

Volltextzugriff (PDF)

Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations

Journal of medicinal chemistry, 2024-02, Vol.67 (3), p.1734-1746

2024

Volltextzugriff (PDF)

The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations

Clinical cancer research, 2024-05, Vol.30 (10), p.2181-2192

2024

Volltextzugriff (PDF)

Abstract LB-493: Blocking the integrin αvβ3-CRAF axis with Cilengitide arrests glioblastoma cells in pro-metaphase

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.LB-493-LB-493

2012

Volltextzugriff (PDF)

Glioblastomas require integrin αvβ3/PAK4 signaling to escape senescence

Cancer research (Chicago, Ill.), 2015-11, Vol.75 (21), p.4466-4473

2015

Volltextzugriff (PDF)

Kinase-independent role for CRAF-driving tumour radioresistance via CHK2

Nature communications, 2015-09, Vol.6 (1), p.8154-8154, Article 8154

2015

Volltextzugriff (PDF)

Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant -IDH2 ( mIDH2 ) newly diagnosed acute myeloid leukemia (ND-AML)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.7501-7501

2020

Volltextzugriff (PDF)

Abstract 2509: Analysis of clonal hematopoiesis-associated mutations in the cell-free DNA of advanced cancer patients

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2509-2509

2019

Volltextzugriff (PDF)

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Blood, 2020-11, Vol.136 (Supplement 1), p.49-51

2020

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Englisch
(55)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

An oxygen-regulated switch in the protein synthesis machinery

Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations

Human cancers converge at the HIF-2α oncogenic axis

MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment

DNMT3a epigenetic program regulates the HIF-2α oxygen-sensing pathway and the cellular response to hypoxia

Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort

HIF-2α: Many cancers, one engine?

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

An oxygen-regulated switch in the protein synthesis machinery

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

The next-generation pan-RAF inhibitor, KIN-2787, is active in class II and class III BRAF mutant models

Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822)

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations

Integrin αvβ3 Drives Slug Activation and Stemness in the Pregnant and Neoplastic Mammary Gland

Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations

The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations

Abstract LB-493: Blocking the integrin αvβ3-CRAF axis with Cilengitide arrests glioblastoma cells in pro-metaphase

Glioblastomas require integrin αvβ3/PAK4 signaling to escape senescence

Kinase-independent role for CRAF-driving tumour radioresistance via CHK2

Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant -IDH2 ( mIDH2 ) newly diagnosed acute myeloid leukemia (ND-AML)

Abstract 2509: Analysis of clonal hematopoiesis-associated mutations in the cell-free DNA of advanced cancer patients

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Suchergebnisse filtern